The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin

被引:21
|
作者
Yamaguchi, Tetsuo [1 ]
Konishi, Hiroe [1 ,2 ]
Aoki, Kotaro [1 ]
Ishii, Yoshikazu [1 ]
Chono, Koji [3 ]
Tateda, Kazuhiro [1 ]
机构
[1] Toho Univ, Sch Med, Dept Microbiol & Infect Dis, Tokyo, Japan
[2] Toho Univ, Grad Sch Med, Div Pediat, Tokyo, Japan
[3] Astellas Pharma Inc, Res Portfolio Planning Drug Discovery & Res, Tsukuba, Ibaraki, Japan
关键词
16S rRNA; Clostridioides difficile; Fidaxomicin; Microbiota; RIBOTYPE; 027; MOUSE MODEL; INFECTION; LACTOFERRIN; STRAIN; SUSCEPTIBILITY; EPIDEMIOLOGY; RECURRENCE; PREVENTION; OUTCOMES;
D O I
10.1016/j.jiac.2019.12.020
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To investigate the effect of vancomycin and fidaxomicin on the diversity of intestinal microbiota in a mouse model of Clostridioides difficile infection. Methods: Mice were divided into 11 models (4 mice per model): 6 uninoculated models and 5 models inoculated with C. difficile BI/NAP1/027. Inoculated models were prepared using intraperitoneal clindamycin followed by inoculation with C. difficile BI/NAP1/027. Uninoculated and C. difficile-inoculated mice received 2 or 7 days' vancomycin or fidaxomicin. Clostridium butyricum MIYAIRI 588 probiotic and lactoferrin prebiotic were administered for 10 days to uninoculated mice. Intestinal microbiome composition was investigated by sequence analyses of bacterial 16S rRNA genes from faeces, and microbiota diversity estimated. Results: In uninoculated, untreated ('normal') mice, Clostridia (57.8%) and Bacteroidia (32.4%) accounted for the largest proportions of gut microbiota. The proportion of Clostridia was numerically reduced in C. difficile-inoculated versus normal mice. Administration of vancomycin to C. difficile-inoculated mice reduced the proportions of Bacteroidia and Clostridia, and increased that of Proteobacteria. Administration of fidaxomicin to C. difficile-inoculated mice reduced the proportion of Clostridia to a lesser extent, but increased that of Bacteroidia. Microbiota diversity was lower in C. difficile-inoculated versus normal mice (164.5 versus 349.1 operational taxonomic units (OTUs), respectively); treatment of C. difficile-inoculated mice with 7 days' vancomycin reduced diversity to a greater extent than did 7 days' fidaxomicin treatment (26.2 versus 134.2 OTUs, respectively). Conclusions: Both C. difficile inoculation and treatment with vancomycin or fidaxomicin reduced microbiota diversity; however, dysbiosis associated with fidaxomicin was milder than with vancomycin. (c) 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:483 / 491
页数:9
相关论文
共 49 条
  • [21] Pulsed dosing and extended daily dosing of oral vancomycin do not facilitate clearance of Clostridioides difficile colonization in mice
    Pearlmutter, Basya S.
    Carlisle, Matthew G.
    Wilson, Brigid M.
    Sangwan, Naseer
    Donskey, Curtis J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (01)
  • [22] In vitro susceptibility of clinical Clostridioides difficile isolates in Israel to metronidazole, vancomycin, fidaxomicin, ridinilazole and ibezapolstat
    Schwartz, Orna
    Azrad, Maya
    Peretz, Avi
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [23] The Initial Gut Microbiota and Response to Antibiotic Perturbation Influence Clostridioides difficile Clearance in Mice
    Tomkovich, Sarah
    Stough, Joshua M. A.
    Bishop, Lucas
    Schloss, Patrick D.
    MSPHERE, 2020, 5 (05)
  • [24] The Role of the Gut Microbiome in Cancer: A Review, With Special Focus on Colorectal Neoplasia and Clostridioides difficile
    Anderson, Sean M.
    Sears, Cynthia L.
    CLINICAL INFECTIOUS DISEASES, 2023, 77 : S471 - S478
  • [25] Quantitative characterization of Clostridioides difficile population in the gut microbiome of patients with C. difficile infection and their association with clinical factors
    Kim, Jieun
    Cho, Youna
    Seo, Mi-Ran
    Bae, Mi Hyun
    Kim, Bongyoung
    Rho, Mina
    Pai, Hyunjoo
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [26] Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models
    Tashiro, Sho
    Taguchi, Kazuaki
    Enoki, Yuki
    Matsumoto, Kazuaki
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (05) : 616 - 622
  • [27] Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection
    Ke, Shanlin
    Pollock, Nira R.
    Wang, Xu-Wen
    Chen, Xinhua
    Daugherty, Kaitlyn
    Lin, Qianyun
    Xu, Hua
    Garey, Kevin W.
    Gonzales-Luna, Anne J.
    Kelly, Ciaran P.
    Liu, Yang-Yu
    GUT MICROBES, 2021, 13 (01) : 1 - 18
  • [28] Role of the microbiome in essential metabolism in the human gut and its implications for Clostridioides difficile infection
    Chopra, Teena
    Hylemon, Phil
    Tillotson, Glenn
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (09):
  • [29] Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE)
    Wolf, Joshua
    Kalocsai, Krisztina
    Fortuny, Claudia
    Lazar, Stefan
    Bosis, Samantha
    Korczowski, Bartosz
    Petit, Arnaud
    Bradford, Daniel
    Croos-Dabrera, Rodney
    Incera, Elodie
    Melis, Joost
    van Maanen, Rob
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (10) : 2581 - 2588
  • [30] Gut microbiome changes in mouse, Mongolian gerbil, and hamster models following Clostridioides difficile challenge
    Wan, Shuangshuang
    You, Peijun
    Shi, Qikai
    Hu, Hui
    Zhang, Lu
    Chen, Leyang
    Wu, Ziyi
    Lin, Shan
    Song, Xiaojun
    Luo, Yongneng
    Wang, Yaxuan
    Ju, Feng
    Jin, Dazhi
    Chen, Yu
    FRONTIERS IN MICROBIOLOGY, 2024, 15